Table of Contents
International Scholarly Research Notices
Volume 2014, Article ID 849149, 9 pages
http://dx.doi.org/10.1155/2014/849149
Research Article

Stability-Indicating HPLC Method for the Simultaneous Determination of HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate, and Rilpivirine Hydrochloride in Pharmaceutical Dosage Forms

Department of Pharmacy, Annamalai University, Chidambaram, Tamil Nadu 608002, India

Received 14 May 2014; Revised 18 August 2014; Accepted 20 August 2014; Published 29 October 2014

Academic Editor: Josep Esteve-Romero

Copyright © 2014 S. Venkatesan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. “Q1AR2: stability testing of new drug substances, products IFPMA,” in Proceedings of the International Conference on Harmonization (ICH '03), Geneva, Switzerland, 2003.
  2. H. B. Fung, E. A. Stone, and F. J. Piacenti, “Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection,” Clinical Therapeutics, vol. 24, no. 10, pp. 1515–1548, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Sharma and L. D. Saravolatz, “Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor,” Journal of Antimicrobial Chemotherapy, vol. 68, no. 2, pp. 250–256, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. UNAIDS, AIDS Epidemic Update, WHO Regional Office Europe, 2009.
  5. S. Raffanti and D. Haas, Anti Microbial Agents: Anti-retroviral Agents, Mcgraw-Hill, New Yor, NY, USA, 2004.
  6. A. Rouzes, K. Berthoin, and F. Xuereb, “Simultaneous analysis antiretroviral drugs,” Journal of Chromatography B, vol. 813, pp. 209–216, 2004. View at Google Scholar
  7. K. Anandakumar, K. Kannan, and T. Vetrichelvan, “Development and validation of emtricitabine and tenofovir Disoproxil fumerate in pure and in fixed dose combination by UV spectrophotometry,” Digest Journal of Nanomaterials and Biostructures, vol. 6, no. 3, pp. 1085–1090, 2011. View at Google Scholar · View at Scopus
  8. A. S. Atul, H. B. Charushila, and J. S. Sanjay, “Application of UV-spectrophotometric methods for estimation of tenofovir disoproxil fumarate in tablets,” Pakistan Journal of Pharmaceutical Sciences, vol. 22, no. 1, pp. 27–29, 2009. View at Google Scholar · View at Scopus
  9. A. J. Pratap Reddy and I. E. Chakravarthy, “New spectrophotometric determination of tenofovir disoproxil fumaratein bulk and pharmaceutical dosage form,” IOSR Journal of Applied Chemistry, vol. 1, no. 2, pp. 29–33, 2012. View at Google Scholar
  10. H. K. Ashour and T. S. Belal, “New simple spectrophotometric method for determination of the antiviral mixture of emtricitabine and tenofovir disoproxil fumarate,” Arabian Journal of Chemistry, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. S. Patel, U. S. Baghel, P. Rajesh, D. Prabhakar, G. Engla, and P. N. Nagar, “Spectrophotometric method development Tenofovir disoproxil fumarate and Emtricitabine in Bulk drug and Tablet dosage form,” International Journal of Pharmaceutical and Clinical Research, vol. 1, no. 1, pp. 28–30, 2009. View at Google Scholar
  12. P. B. Kandagal, D. H. Manjunatha, J. Seetharamappa, and S. S. Kalanur, “RP-HPLC method for the determination of tenofovir in pharmaceutical formulations and spiked human plasma,” Analytical Letters, vol. 41, no. 4, pp. 561–570, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. M. E. Barkil, M.-C. Gagnieu, and J. Guitton, “Relevance of a combined UV and single mass spectrometry detection for the determination of tenofovir in human plasma by HPLC in therapeutic drug monitoring,” Journal of Chromatography B, vol. 854, no. 1-2, pp. 192–197, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. V. Jullien, J.-M. Tréluyer, G. Pons, and E. Rey, “Determination of tenofovir in human plasma by high-performance liquid chromatography with spectrofluorimetric detection,” Journal of Chromatography B, vol. 785, no. 2, pp. 377–381, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. R. W. Sparidans, K. M. L. Crommentuyn, J. H. M. Schellens, and J. H. Beijnen, “Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde,” Journal of Chromatography B, vol. 791, no. 1-2, pp. 227–233, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Joshi, A. P. Nikalje, M. Shahed, and M. Dehghan, “HPTLC method for the simultaneous estimation of emtricitabine and tenofovir in tablet dosage form,” Indian Journal of Pharmaceutical Sciences, vol. 71, no. 1, pp. 95–97, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Delahunty, L. Bushman, and C. V. Fletcher, “Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS,” Journal of Chromatography B, vol. 830, no. 1, pp. 6–12, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Ahindita, P. Aurobinda, K. M. Amit, G. S. Dannana, K. M. Swapna, and C. S. I. Sudam, “Development and Validation of Spectrophotometric methods for determination of Emtricitabine and tenofovir disoproxil fumarate in Bulk and Tablet dosage Form,” International Journal of PharmTech Research, vol. 3, no. 3, pp. 1874–1882, 2011. View at Google Scholar
  19. N. L. Rezk, R. D. Crutchley, and A. D. M. Kashuba, “Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction,” Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 822, no. 1-2, pp. 201–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. H. Droste, R. E. Aarnoutse, and D. M. Burger, “Determination of emtricitabine in human plasma using HPLC with fluorometric detection,” Journal of Liquid Chromatography and Related Technologies, vol. 30, no. 18, pp. 2769–2778, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Ashenafi, A. Verbeek, J. Hoogmartens, and E. Adams, “Development and validation of an LC method for the determination of emtricitabine and related compounds in the drug substance,” Journal of Separation Science, vol. 32, no. 11, pp. 1823–1830, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. N. A. Gomes, V. V. Vaidya, A. Pudage, S. S. Joshi, and S. A. Parekh, “Liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for simultaneous determination of tenofovir and emtricitabine in human plasma and its application to a bioequivalence study,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 3, pp. 918–926, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. U. Seshachalam, B. Haribabu, and K. B. Chandrasekhar, “Development and validation of a stability-indicating liquid chromatographic method for determination of emtricitabine and related impurities in drug substance,” Journal of Separation Science, vol. 30, no. 7, pp. 999–1004, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. G. B. Bhavar, S. S. Pekamwar, K. B. Aher, and S. R. Chaudhari, “Development and validation of UV Spectrophotometric method for estimation of rilpivirine hydrochloride in bulk and pharmaceutical formulations,” American Journal of PharmTech Research, vol. 3, no. 1, pp. 450–458, 2013. View at Google Scholar
  25. G. Somsubhra, B. Sowjanya, P.V. Laxmi, S. Vidyadhar, B. David, and R. Subhadip, “Method development and validation of rilpivirine in bulk and tablet doses form by RP-HPLC method,” Research Journal of Pharmacy and Technology, vol. 6, no. 3, pp. 240–243, 2013. View at Google Scholar · View at Scopus
  26. T. Sudha and P. Shanmugasundram, “Reverse phase high performance and HPTLC methods for the determination of rilpivirine bulk and in tablet dosage form,” World Journal of Pharmaceutical Research, vol. 1, no. 4, pp. 1183–1196, 2012. View at Google Scholar
  27. K. Y. Kavitha, G. Geetha, R. Hariprasad, R. Venkatnarayanan, and M. Kaviarasu, “Development and validation of RP-UPLC analytical method for simultaneous estimation of the emtricitabine, tenofovir disoproxil fumerate and rilpivirine and its pharmaceutical dosageform,” International Research Journal of Pharmacy, vol. 4, no. 1, pp. 150–155, 2013. View at Google Scholar
  28. D. Pranitha, C. Vanitha, P. Francies et al., “Simultaneous estimation of Emtricitabine, Tenofovir disoproxil fumarate and Rilpivirine in bulk form by RP-HPLC method,” Journal of Pharmacy Research, vol. 5, no. 8, pp. 4600–4602, 2012. View at Google Scholar
  29. D. N. Reynolds, K. L. Facchine, J. F. Mullaney, K. M. Alsante, T. D. Hatajik, and M. G. Motto, “Available guidance and best practices for conducting forced degradation studies,” Pharmaceutical Technology, vol. 26, no. 2, pp. 48–56, 2002. View at Google Scholar · View at Scopus
  30. S. Singh and M. Bakshi, “Guidance on conduct of stress tests to determine inherent stability of drugs,” Pharmatech, vol. 24, pp. 1–14, 2000. View at Google Scholar
  31. ICH Q2( R1) Guideline, Validation of Analytical Procedures: Text and Methodology, ICH, Geneva, Switzerland, 2005.